Cholesterol in the crosshairs: the new frontier of cardiovascular care
From New Drugs to Digital Devices: How Medicine is Evolving to Combat Cholesterol and Heart Risks
Innovations in Cholesterol Therapy: A New Chapter in Cardiac Care
The evolution of cholesterol control therapies is revolutionizing the approach to cardiovascular diseases. During the “Lipids in Rome” event, organized by Anmco in collaboration with other scientific institutions, the crucial role of cholesterol in the development of cardiovascular pathologies and the new available therapies were discussed. Emphasis was placed on innovative treatments such as Bempedoic Acid and Inclisiran, which offer greater ease of use and safety, improving cholesterol management and patients’ cardiovascular risk.
Cholesterol in the Young: a Growing Risk
A concerning increase in cardiovascular events has been observed in young individuals, even under the age of 40. High cholesterol is a decisive factor in cardiovascular risk, making it essential for young people to be aware of their levels from an early age. The CardioRisk app, for example, allows for the estimation of an individual’s ten-year risk of heart attacks and strokes, considering all relevant factors. This app can be a valuable tool for developing a personalized strategy to reduce LDL cholesterol, depending on various individual risk factors.
The Digital Heart: Artificial Intelligence and Cardiovascular Health
Digital technology and artificial intelligence are emerging as fundamental tools for managing cardiovascular risk factors and achieving more precise diagnoses. Smartphones are becoming “sentinels” for heart health, capable of monitoring physical activity, heart rate, or blood glucose levels. Furthermore, the use of advanced algorithms for analyzing ECG, PET, and MRI data is gaining prominence, supporting doctors in diagnosis and treatment customization.
The Future of Cardiology: Prevention and Personalization
Cardiology is experiencing an era of significant changes, with an increasing focus on prevention and personalized care. The challenge is to integrate patients’ clinical data with digital technologies to obtain more detailed information about individual risks of heart disease and the effectiveness of therapies. This personalized and preventive approach could lead to a significant decrease in the prevalence of cardiovascular diseases and improve the quality of life for patients.
The battle against cholesterol and cardiovascular risks is entering a new era thanks to advancements in pharmacological and digital medicine. These innovations not only offer hope for more effective management of cardiovascular diseases but also underscore the importance of a more personalized and preventive approach to cardiac health care.